Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
161 hedge funds and large institutions have $2.18B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 64 increasing their positions, 54 reducing their positions, and 22 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 54
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
6% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $21.3M
4% less funds holding
Funds holding: 168 → 161 (-7)
13% less capital invested
Capital invested by funds: $2.51B → $2.18B (-$333M)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.6M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.39M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$9.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$19.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$18.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.9M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$12.5M |
DCPH Hedge Fund Activity: Q3 2020 in Review
161 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2020, worth a combined $2.18B — down 13% from $2.51B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of DCPH and 16 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 64 added.
The largest buyer was Fidelity Investments, adding an estimated $17.2M. The largest seller was Dimensional Fund Advisors, cutting an estimated $19.8M.
- 161 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2020, down from 168 in Q2 2020.
- Funds reported $2.18B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 13% quarter-over-quarter.
- 16 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 22 closed out, a net change of -6 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $17.2M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Dimensional Fund Advisors, an estimated $19.8M sold.
Based on aggregated 13F filings for Q3 2020.